RepliCel Life Sciences Past Earnings Performance
Past criteria checks 3/6
RepliCel Life Sciences has been growing earnings at an average annual rate of 30.5%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 0.4% per year.
Key information
30.5%
Earnings growth rate
36.1%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 0.4% |
| Return on equity | n/a |
| Net Margin | 215.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How RepliCel Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | 1 | 1 | 0 |
| 31 Mar 24 | 0 | 0 | 1 | 0 |
| 31 Dec 23 | 0 | 0 | 1 | 1 |
| 30 Sep 23 | 0 | 0 | 1 | 1 |
| 30 Jun 23 | 0 | 0 | 1 | 1 |
| 31 Mar 23 | 0 | -1 | 1 | 1 |
| 31 Dec 22 | 0 | -1 | 1 | 1 |
| 30 Sep 22 | 0 | -4 | 1 | 1 |
| 30 Jun 22 | 0 | -4 | 1 | 1 |
| 31 Mar 22 | 0 | -4 | 2 | 1 |
| 31 Dec 21 | 0 | -4 | 2 | 1 |
| 30 Sep 21 | 0 | -3 | 1 | 1 |
| 30 Jun 21 | 0 | -3 | 1 | 1 |
| 31 Mar 21 | 0 | -3 | 1 | 1 |
| 31 Dec 20 | 0 | -2 | 1 | 1 |
| 30 Sep 20 | 0 | -2 | 1 | 1 |
| 30 Jun 20 | 0 | -2 | 1 | 1 |
| 31 Mar 20 | 0 | -3 | 1 | 2 |
| 31 Dec 19 | 0 | -3 | 1 | 2 |
| 30 Sep 19 | 0 | -3 | 2 | 2 |
| 30 Jun 19 | 0 | -3 | 2 | 2 |
| 31 Mar 19 | 0 | -3 | 2 | 1 |
| 31 Dec 18 | 0 | -3 | 2 | 1 |
| 30 Sep 18 | 0 | -2 | 2 | 1 |
| 30 Jun 18 | 0 | -3 | 2 | 1 |
| 31 Mar 18 | 0 | -5 | 3 | 2 |
| 31 Dec 17 | 0 | -6 | 3 | 3 |
| 30 Sep 17 | 0 | -7 | 4 | 3 |
| 30 Jun 17 | 0 | -7 | 4 | 2 |
| 31 Mar 17 | 0 | -5 | 4 | 1 |
| 31 Dec 16 | 0 | -4 | 3 | 1 |
| 30 Sep 16 | 0 | -4 | 2 | 1 |
| 30 Jun 16 | 0 | -4 | 3 | 2 |
| 31 Mar 16 | 0 | -5 | 3 | 2 |
| 31 Dec 15 | 0 | -5 | 3 | 2 |
| 30 Sep 15 | 0 | -5 | 3 | 2 |
| 30 Jun 15 | 0 | -5 | 3 | 2 |
| 31 Mar 15 | 0 | -5 | 3 | 2 |
| 31 Dec 14 | 0 | -5 | 3 | 2 |
| 30 Sep 14 | 0 | -5 | 3 | 2 |
| 30 Jun 14 | 4 | -1 | 3 | 2 |
| 31 Mar 14 | 4 | 0 | 2 | 2 |
| 31 Dec 13 | 4 | 0 | 2 | 1 |
Quality Earnings: REPC.F has high quality earnings.
Growing Profit Margin: REPC.F became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: REPC.F has become profitable over the past 5 years, growing earnings by 30.5% per year.
Accelerating Growth: REPC.F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: REPC.F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: REPC.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.